Primary:
- To determine if treatment with Haelan (fermented soy product) can decrease the severity
of poor appetite measured using a visual analog scale (VAS) of 0 to 100 mm (0 mm = best,
100 mm = worst) at week 4 +/- 5 days.
- To determine if treatment with Haelan can decrease the severity of nausea, fatigue, and
improve patients' overall sense of well being measured using a VAS of 0 to 100 mm (0 mm
= best, 100 mm = worst) at week 4 +/- 5 days.
- To determine if treatment with Haelan can increase patient's calorie intake, albumin,
pre-albumin, anthropometric measure, lean body mass (measured by bio-impedence
analysis), and weight at week 4+/- 5 days.
- To determine if treatment with Haelan can decrease patient's Functional assessment of
anorexia/cachexia therapy subscales or (FAACT) and the Functional Assessment of Chronic
Illness Therapy with fatigue subscales (FACIT-F) at week 4+/- 5 days.
- To assess the feasibility of accrual, and adherence to the Haelan consumption.
Secondary:
- Determine the plasma isoflavone activity, 12-MTA and 13-MTA of these patients.
- Correlate the biologic modulation of peripheral blood lymphocyte NF-kB by Haelan with
primary outcome in these patients.
- To determine if treatment with Haelan can increase patient's functional status at week
4+/- 5 days.